natgillin/translations-raw huggingface dataset:
Gentagen behandling er kun indiceret i tilfælde hvor blandingsinfektioner med coccidia og rundorme fortsat er mistænkt eller påvist som beskrevet i afsnit 4.2.
Repeated treatment is indicated only if mixed infection with coccidia and nematodes, as described in section 4.2, is still suspected or demonstrated.
Gentagen behandling er kun indiceret når, blandingsinfektioner med coccidia og rundorme fortsat er mistænkt (af dyrlægen) eller påvist.
Repeated treatment is indicated only if mixed infections with coccidia and roundworms continue to be suspected (by the veterinarian) or demonstrated.
Gentagen behandling kan overvejes i tilfælde med tilbagevendende hyperkalcæmi eller utilstrækkelig behandlingseffekt.
Repeated treatment may be considered in case of recurrent hypercalcaemia or insufficient efficacy.
Gentagen brug: Data vedrørende genbehandling af patienter med [90Y] radioaktivt mærket Zevalin er ikke tilgængelig.
Repeated use: Data on the re-treatment of patients with [90Y]-radiolabeled Zevalin are not available.
Gentagen brug: Data vedrørende genbehandling af patienter med [90Y] radioaktivt mærket Zevalin er ikke tilgængelige.
Repeated use: Data on the re-treatment of patients with [90Y]-radiolabelled Zevalin are not available.
Gentagen dosering (otte injektioner) med 14 dages intervaller ved 5 gange den anbefalede dosis til unge katte tåltes udmærket.
Repeated dosing (eight administrations) in 14-day intervals at five times the recommended dose was tolerated well in young cats.
Gentagen indgift af infliximab (5 mg/kg ved 0, 2 og 6 uger i fistulerende Crohns sygdom, 3 eller 10 mg/kg hver 4. eller 8. uge i reumatoid arthritis) resulterede i en let akkumulering af infliximab i serum efter den anden dosis.
Repeated administration of infliximab (5 mg/kg at 0, 2 and 6 weeks in fistulising Crohn´s disease, 3 or 10 mg/kg every 4 or 8 weeks in rheumatoid arthritis) resulted in a slight accumulation of infliximab in serum after the second dose.
Gentagen infusion hver 8. til 24.
Every 24 hours, at least
Gentagen oral indgift af leflunomid til mus i op til 3 måneder, og til rotter og hunde i op til 6 måneder og aber i op til 1 måned viste, at de overvejende målorganer for toksicitet var rygmarv, blod, mave- tarmkanalen, hud, milt, thymus og lymfekirtler.
Repeated oral administration of leflunomide to mice for up to 3 months, to rats and dogs for up to 6 months and to monkeys for up to 1 month's duration revealed that the major target organs for toxicity were bone marrow, blood, gastrointestinal tract, skin, spleen, thymus and lymph nodes.
Gentagen peroral indgift af robenacoxib til hunde i doser på 2-10 mg/kg i 6 måneder forårsagede ingen ændring i blodprofilen, hverken akkumulation af robenacoxib eller enzyminduktion.
Repeated oral administration of robenacoxib to dogs at dosages of 2–10 mg/kg for 6 months produced no change in the blood profile, with neither accumulation of robenacoxib nor enzyme induction.
Gentagen samtidig administration af linagliptin og metformin medførte ingen farmakokinetisk ændring af betydning hos raske frivillige eller hos patienter.
Co- administration of multiple doses of linagliptin and metformin did not meaningfully alter the pharmacokinetics of either linagliptin or metformin in healthy volunteers and patients.
Gentagen subkutan indgift i doser på 2-20 mg/kg forårsagede ingen ændring i blodprofilen, hverken bioakkumulation af robenacoxib eller enzyminduktion.
Repeated subcutaneous administration at dosages of 2–20 mg/kg produced no change in the blood profile, with neither bioaccumulation of robenacoxib nor enzyme induction.
Gentages hver 12.-24. time i mindst 1 døgn, indtil det skønnes, at blødningen er ophørt bedømt ud fra smerter eller heling.
Repeat infusion every 12 - 24 hours for at least 1 day, until the bleeding episode as indicated by pain is resolved or healing is achieved.
Gentages hver 24.-72. time i den første uge; herefter vedligeholdelsesdosis 1-2 gange om ugen, indtil blødningen stopper, og heling er opnået.
Repeat every 24 – 72 hours for the first week, and then maintenance dose 1 – 2 times per week until bleeding stops and healing is achieved.
Gentages hver 24.-72. time i den første uge; herefter vedligeholdelsesdosis ugentligt, indtil blødningen stopper, og heling er opnået.
Repeat every 24 – 72 hours for the first week, and then maintenance dose weekly until bleeding stops and healing is achieved.
Gentages hver 24.–72.time i den første uge; herefter vedligeholdelsesdosis ugentligt, indtil blødningen stopper, og heling er opnået.
Repeat every 24 – 72 hours for the first week, and then maintenance dose weekly until bleeding stops and healing is achieved.
Gentages yderligere 3 gange hver med 14 dages mellemrum.
If required, treatment may be repeated at 14 day intervals up to a further three times.
Gentaget dosering af adefovirdipivoxil 10 mg dagligt påvirkede ikke adefovirs farmakokinetik.
Repeated dosing of adefovir dipivoxil 10 mg daily did not influence the pharmacokinetics of adefovir.
Gentaget intermitterende behandling er undersøgt for op til 4 intermitterende behandlingsforløb.
Repeated intermittent treatment has been studied up to 4 intermittent courses.
Gentaget, intermitterende behandling er undersøgt for op til 4 intermitterende behandlingsforløb.
Repeated intermittent treatment has been studied up to 4 intermittent treatment courses.
Gentagne behandlingsforløb med MabThera er mulige.
Repeated courses of treatment with MabThera are possible.
Gentagne behandlingsserier
Multiple courses
Gentagne blodtransfusioner kan være nødvendige hos patienter med forskellige slags anæmier (blodmangel) (fx thalassæmi, seglcelleanæmi eller myelodysplastiske syndromer (MDS)).
Repeated blood transfusions may be necessary in patients with various types of anaemia (for example thalassaemia, sickle cell disease or myelodysplastic syndromes (MDS)).
Gentagne blodtransfusioner.
Patients receiving repeated blood transfusions.
Gentagne doser af diltiazem (240 mg to gange daglig), verapamil (240 mg én gang daglig) og nifedipin (20 mg to gange daglig) resulterede i en stigning i dronedaron-plasmakoncentrationen med henholdsvis 1,7-, 1,4- og 1,2 gange.
Repeated doses of diltiazem (240 mg twice daily), verapamil (240 mg once daily) and nifedipine (20 mg twice daily) resulted in an increase in dronedarone exposure of 1.7-, 1.4- and 1.2-fold, respectively.
Gentagne doser grapefrugtjuice på 300 ml tre gange daglig resulterede i en 3-dobbelt stigning i dronedaron- plasmakoncentrationen.
Repeated doses of 300 ml of grapefruit juice three times daily resulted in a 3-fold increase in dronedarone exposure.
Gentagne doser på 15 mg/kg hver 3. uge blev administreret uden yderligere bivirkninger.
Repeated dosing of 15 mg/kg every 3 weeks has been administered without additional adverse drug reactions.
Gentagne doser på 200 mg ketoconazol daglig resulterede i en 17-dobbelt stigning i dronedaron- plasmakoncentrationen.
Repeated doses of 200 mg ketoconazole daily resulted in a 17-fold increase in dronedarone exposure.
Gentagne doser på 7.200 mg/dag var ikke forbundet med alvorlige tegn eller symptomer.
Multiple dosing of 7,200 mg/day was associated with no major signs or symptoms.
Gentagne doser skal overvejes, hvis en patient oplever respons på behandlingen efterfulgt af et synstab i visuel skarphed og efter lægens skøn kan få gavn af en gentagelse af behandlingen uden at blive udsat for væsentlig risiko (se pkt.
Repeat doses should be considered when a patient experiences a response to treatment followed subsequently by a loss in visual acuity and in the physician’s opinion may benefit from retreatment without being exposed to significant risk (see section 5.1).
Gentagne doser teriflunomid gav et fald i middel-caffein-Cmax og -AUC på henholdsvis 18 % og 55 %, hvilket tyder på, at teriflunomid kan være en svag CYP1A2-induktor in vivo.
Repeated doses of teriflunomide decreased mean Cmax and AUC of caffeine (CYP1A2 substrate) by 18% and 55%, respectively, suggesting that teriflunomide may be a weak inducer of CYP1A2 in vivo.
gentagne doser Victrelis 800 mg tre
multiple doses)
gentagne doser Victrelis 800 mg tre
Victrelis 800 mg three times daily
Gentagne doseringer (otte injektioner) med 14 dages mellemrum ved 5 gange den anbefalede dosis til unge hunde tåltes udmærket.
Repeated dosing (eight administrations) in 14-day intervals at five times the recommended dose was tolerated well in young dogs.
Gentagne gange injicerer mindre insulin, end du har brug for
Repeatedly inject less insulin than you need.
Gentagne gange injicerer mindre insulin, end du har brug for.
Repeatedly inject less insulin than you need.
Gentagne gange tager mindre insulin, end du har brug for.
Repeatedly take less insulin than you need.
Gentagne studier (N=23)
Repeat Evaluation (N=23)
Gentamicinsulfat
Gentamicin sulfate
Gentamycin max...........................................................................................................................
Gentamicin, at most.......................................................................................................................
Gentamycin max............................................................................................................................
Gentamicin, at most.......................................................................................................................
Gentamycin max..............................................................................................................................
Gentamicin, at most..........................................................................................................................
Gentamycin max...............................................................................................................................
Gentamicin, at most..........................................................................................................................
Gentamycin max................................................................................................................................
Gentamicin, at most..........................................................................................................................
Gentamycin max.................................................................................................................................
Gentamicin, at most..........................................................................................................................
Gentamycin max...............................................................................................................................16,5g
Gentamicin, at most.......................................................................................................................
Gentamycin max…………………………………………………………….....................……………….…..28g
Gentamicin, at most..........................................................................................................................
Gentamycin max…………………………………………………………….....................……………….…..34g
Gentamicin, at most..........................................................................................................................
Gentamycin max…………………………………………………………………………….….….
Gentamicin, at most..........................................................................................................................
Genuair-inhalatoren er en anordning med flere komponenter, der er fremstillet af plastik (polycarbonat, acrylonitril-butadien-styren, polyoxymethylen, polyesterbutylenterephthalat, polypropylen, polystyren) og rustfrit stål.
The Genuair inhaler is a multicomponent device made of plastic (polycarbonate, acrylonitrile- butadiene-styrene, polyoxymethylene, polyester-butylene-terephthalate, polypropylene, polystyrene) and stainless steel.
Genuair-inhalatoren er en anordning med flere komponenter, der er fremstillet af plastik (polycarbonat, acrylonitril-butadien-styren, polyoxymethylen, polyesterbutylenterephthalat, polypropylen, polystyren) og rustfrit stål.
The Genuair inhaler is a multicomponent device made of plastic (polycarbonate, acrylonitrile-butadiene- styrene, polyoxymethylene, polyester-butylene-terephthalate, polypropylene, polystyrene) and stainless steel.
Genuair-inhalatoren er udstyret med en dosisindikator som viser dig, cirka hvor mange doser er tilbage i inhalatoren.
The Genuair inhaler is equipped with a dose indicator to show you approximately how many doses are left in the inhaler.
Genuair-inhalatoren er udstyret med en dosisindikator som viser dig, cirka hvor mange doser, der er tilbage i inhalatoren.
The Genuair inhaler is equipped with a dose indicator to show you approximately how many doses are left in the inhaler.
Genuair-inhalatoren er udstyret med en dosisindikator, som viser cirka hvor mange doser, der er tilbage i inhalatoren.
The Genuair inhaler has a dose indicator to show approximately how many doses are left in the inhaler.
Genuair-inhalatoren er udstyret med en dosisindikator, som viser dig, cirka hvor mange doser, der er tilbage i inhalatoren.
The Genuair inhaler is equipped with a dose indicator to show you approximately how many doses are left in the inhaler.
Genuair-inhalatoren: brugsanvisning
The Genuair inhaler: instructions for use
Genuairinhalatoranordningen er hvid med en indbygget dosisindikator og en grøn doseringsknap.
The Genuair inhaler device is white coloured with an integral dose indicator and a green dosage button.
Genvoya 150 mg/150 mg/200 mg/10 mg filmovertrukne tabletter
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets
Genvoya bør ikke administreres samtidigt med lægemidler, som indeholder tenofovirdisoproxil (som fumarat), lamivudin eller adefovirdipivoxil, der anvendes til behandling af virusinfektion med HBV.
Genvoya should not be administered concomitantly with medicinal products containing tenofovir disoproxil (as fumarate), lamivudine or adefovir dipivoxil used for the treatment of HBV infection.
Genvoya bør ikke indgives samtidigt med lægemidler, som indeholder tenofovirdisoproxil (som fumarat), lamivudin eller adefovirdipivoxil, og som anvendes til behandling af HBV-infektion.
Genvoya should not be administered concomitantly with medicinal products containing tenofovir disoproxil (as fumarate), lamivudine or adefovir dipivoxil used for the treatment of HBV infection.
Genvoya er en enkelt tablet til behandling af infektion med humant immundefekt virus 1 (hiv 1) hos voksne og unge i alderen 12 år og ældre, som vejer mindst 35 kg.
Genvoya is a single tablet for the treatment of human immunodeficiency virus 1 (HIV-1) infection in adults and adolescents 12 years of age and older, who weigh at least 35 kg.
Genvoya indeholder de aktive stoffer elvitegravir, cobicistat, emtricitabin and tenofoviralafenamid.
Genvoya contains the active substances elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide.
Genvoya nedsætter mængden af hiv i Deres krop.
Genvoya reduces the amount of HIV in your body.
Genvoya opfyldte kriterierne for non-inferioritet ved at opnå hiv 1-rna < 50 kopier/ml, sammenlignet med E/C/F/TDF.
Genvoya met the non-inferiority criteria in achieving HIV-1 RNA < 50 copies/mL when compared to E/C/F/TDF.
Genvoyas sikkerhed og virkning hos børn under 12 år, eller der vejer < 35 kg, er endnu ikke klarlagt.
The safety and efficacy of Genvoya in children younger than 12 years of age, or weighing < 35 kg, have not yet been established.
Genvoyas sikkerhed og virkning hos patienter med signifikant, tilgrundliggende leversygdom er ikke klarlagt.
The safety and efficacy of Genvoya in patients with significant underlying liver disorders have not been established.
Genzyme Biopharma SRL Tel: +40 21243 4228
Genzyme Biopharma SRL Tel: +40 212 43 42 28
Genzyme Biosurgery ApS, Oliefabriksvej 51B, DK-2770 Kastrup, Danmark
Genzyme Biosurgery ApS, Oliefabriksvej 51B, DK-2770 Kastrup, Denmark
Genzyme Europe B.V., Gooimeer 10, 1411 DD Naarden, Holland.
Genzyme Europe B.V., Gooimeer 10, 1411 DD Naarden, the Netherlands
Genzyme Europe B.V., Gooimeer 10, 1411 DD, Naarden, Holland
Genzyme Europe B.V., Gooimeer 10, 1411 DD, Naarden, the Netherlands
Genzyme Europe B.V., Gooimeer 10, 1411DD, Naarden, Holland
Genzyme Europe B.V., Gooimeer 10, 1411DD, Naarden, The Netherlands
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD Naarden, Holland
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD Naarden, The Netherlands
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD Naarden, Holland
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD Naarden, The Netherlands.
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD Naarden, Holland.
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD Naarden, The Netherlands.
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD, Naarden, Holland
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD, Naarden, The Netherlands
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD, Naarden, Holland.
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD, Naarden, The Netherlands.
Genzyme Europe B.V., Gooimeer 10, NL-1411DD Naarden, Holland.
Genzyme Europe B.V., Gooimeer 10, NL-1411DD Naarden, The Netherlands
Genzyme Europe BV, Gooimeer 10, NL-1411 DD Naarden, Holland
Genzyme Europe BV, Gooimeer 10, 1411 DD Naarden, Netherlands
Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Irland
Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland
Genzyme Limited, 37 Hollands Road, Haverhill, Suffolk CB9 8PU, Storbritannien Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland
Genzyme Limited, 37 Hollands Road, Haverhill, Suffolk CB9 8PU, United Kingdom Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland
Genzyme Ltd.
The Netherlands
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, England
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, United Kingdom
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, Storbritannien
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, United Kingdom
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, Storbritannien Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Irland
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, United Kingdom Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, Storbritannien Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Irland
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, United Kingdom Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland‌
Genzyme Srl (Italia/Italja), Tel: +39 059 349811
Genzyme Srl (Italia/Italja), Tel: +39 059 349 811
Genzyme Therapeutics Ltd, 4620 Kingsgate, Cascade Way, Oxford Business Park South, Oxford, OX4 2SU, Storbritannien
Genzyme Therapeutics Ltd, 4620 Kingsgate, Cascade Way, Oxford Business Park South, Oxford, OX4 2SU, United Kingdom
Geometrisk gennemsnitlig ændring (%)
Dose reduction of vinca alkaloids
Geometrisk gennemsnitlig ændring (%)
Geometric mean changes (%)
Geometrisk gennemsnitligt Cmin for indinavir (0,33 mg/l), når det blev givet sammen med ritonavir og efavirenz, var højere end det gennemsnitlige historiske Cmin (0,15 mg/l), når indinavir blev givet alene ved 800 mg q8h.
indinavir (0.33 mg/l) when given with ritonavir and efavirenz was higher than the mean historical Cmin (0.15 mg/l) when indinavir was given alone at 800 mg q8h.
Geometrisk middel- titer
Geometric mean titer
geometrisk middelstigning
(39.1; 75.5) (78.6; 99.2)
geometrisk middelstigning
9.0 (5.6; 14.5)
Geometrisk middelværdi (%CV†)
Geometric mean (%CV†)
Geometrisk middelværdi (%CV†) C12t (nM)
Geometric mean (%CV†)
Geometrisk middelværdi ændring (%)
Geometric mean change (%)
Geometrisk middelændring (%)
Geometric mean change (%)
Geometrisk middelændring (%) (Mulig mekanisme)
Geometric mean change (%) (Possible mechanism)
Geometrisk standardafvigelse ±SD
Geometric Standard Deviation ±SD
Geometriske middeltitre (ved hjælp af en neutraliserende plaque-reduktionsprøve - PRNT)
Geometric mean titer (by plaque reduction neutralization test)
Geometriske middeltitre var signifikant højere på dag 28 hos forsøgspersoner <50 end hos forsøgspersoner
Geometric mean titers were significantly higher at Day 28 in subjects aged <50 years than those aged ≥50 years in the JE VAX group (80.9 vs.
Geometriske middelværdier (95 % CI)
GMR (95% CI)
George Borg BarthetAssociated Drug Company Ltd.
Eesti (Estonia) Generics [UK] Ltd.
Gepubliceerde frequenties voor de genotypes met een verminderd CYP2C19- metabolisme bedragen ongeveer 2% voor Kaukasiërs, 4% voor het negroïde ras en 14% voor Chinezen.
Published frequencies for the poor CYP2C19 metaboliser genotypes are approximately 2% for Caucasians, 4% for Blacks and 14% for Chinese.
gere gere
Medicinalroduct n
Geriatrisk population (≥65 år)
Elderly population (≥65 years of age)
Germany
2300 København S
Gestationsalder under 24 eller over 33 fuldbårne uger
Gestational age below 24 or over 33 completed weeks
Gevallen van onverenigbaarheid
Incompatibilities
Gevinst på ≥15 bogstaver i synsstyrke (%)a
Gain of ≥15 letters in visual acuity (%)a
Gewerbestrasse 7 FL-9496 Balzers Liechtenstein
Finox Biotech AG Gewerbestrasse 7 FL-9496 Balzers Liechtenstein
GFR ≥ 30 ml/min/1,73 m2; n = 179) eller svært (30 > GFR ≥ 15 ml/min/1,73 m2; n = 2) nedsat nyrefunktion i forhold til patienter med normal nyrefunktion (GFR ≥ 90 ml/min/1,73 m2; n = 342).
The effect of renal impairment on the CL of nivolumab was evaluated in patients with mild (GFR < 90 and ≥ 60 mL/min/1.73 m2; n = 379), moderate (GFR < 60 and ≥ 30 mL/min/1.73 m2; n = 179), or severe (GFR < 30 and ≥ 15 mL/min/1.73 m2; n = 2) renal impairment compared to patients with normal renal function (GFR ≥ 90 mL/min/1.73 m2; n = 342) in population PK analyses.
GH <2,5 µg/l og IGF-1 ≤ULN
GH <2.5 μg/l and IGF-1 ≤ULN
GH <2,5 µg/l og normaliseret IGF-1*
GH <2.5 μg/l and normalised IGF-1
GH<2,5 μg/l og normaliseret IGF-1*
GH<2.5 μg/l and normalised IGF-1
GHB havde ingen effekt på parring, almen fertilitet eller spermparametre og forårsagede ikke embryo- føtal toksicitet hos rotter, som blev eksponeret for op til 1.000 mg/kg/dag GHB (1,64 gange den humane eksponering udregnet i ikke-gravide dyr).
GHB had no effect on mating, general fertility or sperm parameters and did not produce embryo- foetal toxicity in rats exposed to up 1000 mg/kg/day GHB (1.64 times the human exposure calculated in nonpregnant animals).
ghed, hovedpine
vision blurred
GI blødning
GI bleeding
GI-reaktioner kan
related GI reactions
Gift med studiepartner
Married to study partner
Giftstoffer i blodet som en komplikation til infektion.
Toxins in the blood as a complication of infection.
gigt
arthritis
gigt unormale blodprøver (nedsat glucose, forhøjet kalium, unormale leverfunktionsprøver, forhøjet antal hvide blodceller, f.eks. eosinofili)
gout abnormal blood tests (decreased glucose, elevated potassium, abnormal liver function, elevated type of white blood cell i.e. eosinophilia)
gigtmedicin.
arthritis medicines.
Gigtmidler
Antigout agent
Gilberts sygdom) kan have forhøjede serumkoncentrationer af bilirubin og skal behandles med forsigtighed.
Gilbert’s disease) may exhibit increased serum concentrations of bilirubin and must be treated with caution.
Gilead Sciences Belgium SPRL-BVBA Tél/Tel: + 32 (0) 2 401 35 79
Gilead Sciences Netherlands B.V. Tel: + 31 (0) 20 718 36 98
Gilead Sciences Belgium SPRL-BVBA Tél/Tel: + 32 (0)24 01 35 50
Gilead Sciences Belgium SPRL-BVBA Tél/Tel: + 32 (0) 24 01 35 50
Gilead Sciences GmbH Tel: + 49 (0) 89 899890-0
Gilead Sciences International Ltd Tel: + 44 (0) 20 7136 8820
Gilead Sciences International Ltd Tel: + 421 232 121 210
Τηλ: + 30 210 8930 100
Gilead Sciences Netherlands B.V. Tel: + 31 (0)20 718 36 98
Gilead Sciences Netherlands B.V. Tel: + 31 (0) 20 718 36 98
Gilead Sciences Sweden AB Puh/Tel: + 46 (0) 8 5057 1849
Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849
Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849
Gilead Sciences GmbH Tel: + 49 (0) 89 899890-0
Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849
Gilead Sciences Sweden AB Puh/Tel: + 46 (0) 8 5057 1849
Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849
Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1849